Albert David formalizes Amit Mahla as Whole-time Director and CEO for 5 years

Ceo Appointed ExternalManagement Changes View source PDF

ALBERTDAVD · price

Loading chart…

▲ positive · ▼ negative · ● neutral filings · teal = economic event · numbered = multiple that day (click to pick). Times IST.

Price reaction · full curve 14 horizons · vs prior close

+0.5%1-day move

₹710.50

prior close

—

base price

After-mkt

timing

5m10m15m30m1D2D3D4D5D7D15D1M2M3M

————+0.5+0.2-0.7-0.4-1.8+0.9-2.2-3.3——

Up moveDown movePending

AI summary

Board approved Mr. Amit Mahla as Additional Director and Whole-time Director and CEO for 5 years (June 19, 2026 to June 18, 2031), subject to shareholder approval at the 87th AGM. He was already named CEO on May 12, 2026. He has 28 plus years of pharma experience with stints at Cipla, Emcure, Glenmark, Alembic, Sun Pharma, and JB Pharma. Remuneration is fixed till March 31, 2027.

Likely market impact

Formalizes an experienced external CEO, signaling leadership continuity and strategic focus for the company.